CD274 and neoplasm: The early phase IB KEYNOTE-028 basket study of patients with select PD-L1 positive advanced or metastatic tumors, including BTC, suggested pembrolizumab had promising anti-tumor activity, with an overall response rate (ORR) of 13.0% [46,47].